Bouncing back from late-phase fail, Minoryx pockets €51M to guide rare disease drug to market

Minoryx has persuaded investors to overlook the failure of its phase 2/3 clinical trial, enabling it to reel in 51 million euros ($55 million) to support attempts to bring the rare disease drug to market in Europe and the U.S.